Harvard Medical School And Cellectricon Collaborate Around Whole-Genome RNAi Screening Technology - Cellaxess(R)HT

Cellectricon, a leading provider of automated screening solutions for
drug discovery, today announced its collaboration with Harvard Medical
School, the ICCB-Longwood Screening Facility ("ICCB-L"). Harvard Medical
School (ICCB-L) will utilize the Cellaxess(R)HT system, the world's first
system for high throughput transfection enabling reagent-free delivery of
genetic material to a wide range of biologically relevant cell types.





"We are excited about the collaboration with Cellectricon and the
opportunity we have to evaluate Cellaxess(R)HT for genome-wide RNAi delivery
to biologically relevant cell types," says Caroline Shamu, Director of
ICCB-L.





"Cellectricon is extremely proud to collaborate with a world-class
research institution such as Harvard Medical School (ICCB-L)," says Jonas
Ohlsson, CEO at Cellectricon. "We look forward to jointly advance the RNAi
research area by our technology, as we're confident that Cellaxess(R)HT will
aid in the generation of more relevant results from RNAi screening
campaigns."





About Cellectricon





Cellectricon AB, a Swedish biotech company, successfully provides
groundbreaking products to the pharmaceutical and biotechnology industries.
The company utilizes state-of-the-art interfaces to biological systems by
employing novel microfluidic technologies. This enables completely new types
of assays and devices with superior performance characteristics and
robustness. Cellectricon's products address critical bottlenecks in the drug
discovery process and have been adopted by top-reference customers, including
nine of the top ten pharmaceutical companies. In 2007, the company increased
its annual revenue by almost 50%. In 2008-2009 the company is launching two
pioneering large-scale screening platforms developed in close collaboration
with leaders in the pharmaceutical industry. Used in pre-clinical
pharmaceutical development, the Cellaxess(R)HT System enables high throughput
RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug
discovery.



Cellectricon AB